Drug Compounders Monitor State Debates On Office-Use Limits, Permits

FDA Week - 04/12/2013

Drug compounders are monitoring how state legislatures reference U.S. Pharmacopeia standards and restrict products produced for office use -- a requirement sidestepped by compounders tied to a recent outbreak -- as well as new mandates for sterile compounding permits, an International Academy of Compounding Pharmacists official said, responding to a flurry of state activity in recent months. Action by the National Association of Boards of Pharmacy to better track pharmacies has also assuaged some concerns that emerged after last year's meningitis outbreak, sources said.1234 words Subscription required here